Oncolytic Virus Therapy with HSV-1 for Hematologic Malignancies

溶瘤病毒 病毒学 生物 单纯疱疹病毒 白血病 病毒 细胞培养 癌症研究 免疫学 遗传学
作者
Ryo Ishino,Yumi Kawase,Toshio Heike,Naoshi Sugimoto,Maki Oku,Shumpei Uchida,Osamu Imataki,Akihito Matsuoka,Teruhisa Taoka,Kimihiro Kawakami,Tomoki Todo,Akifumi Takaori‐Kondo,Norimitsu Kadowaki
出处
期刊:Blood [Elsevier BV]
卷期号:134 (Supplement_1): 3242-3242 被引量:1
标识
DOI:10.1182/blood-2019-127754
摘要

Background: Oncolytic virus (OV) is an attractive and rapidly developing antitumor therapy. OVs preferentially replicate in tumor cells and exhibit a tumoricidal activity without damaging normal cells. G47Δ is a herpes simplex virus (HSV)-1 genetically engineered to enhance tumor selectivity and immunogenicity. Clinical trials of G47Δ have been conducted for brain and prostate cancers. Anecdotal reports that leukemia and lymphoma shrink following viral infection imply effectiveness of OV therapy against hematological malignancies. Aim: We examined whether G47Δ has the potential for treatment of hematological malignancies. Methods: T-01, an HSV-1 containing modification in the same genes as G47Δ, was used in this study. To assess T-01 infectivity and cytotoxicity for hematological tumor cells, cell lines and clinical samples were incubated with the virus. T-GFP, T-01 containing the GFP gene, was used to quantify the viral infectivity. To examine antitumor activity in vivo, we injected T-01 into subcutaneously inoculated tumors in immunodeficient SCID-Beige mice. To identify the differences between T-01-susceptible and resistant cells, we examined the involvement of HSV entry receptors (nectin-1, HVEM, PILRα, non-muscle myosin IIA and IIB) and antiviral molecules (cGAS-STING and PKR-eIF2α pathways). Jurkat and THP-1 cell lines were infected with the lentivirus vector expressing shRNA against nectin-1. Ramos and RL-male-1 (murine leukemia) cell lines were infected with the lentivirus vector expressing human nectin-1. Results: 15 of 21 cell lines from T-, B-, and myeloid-derived hematological malignancies were infected and killed by T-01. 8 of 15 clinical samples were also killed by T-01, and all the susceptible samples were from relapsed patients. Growth of the subcutaneous GRANTA-519 and ED-40515 (ATL cell line) tumors was significantly suppressed by intratumor injection of T-01. The expression level of nectin-1, the amount of viral entry, and the cytotoxicity were positively correlated in cell lines and clinical samples (Figure 1). In agreement with this, knockdown of nectin-1 decreased the amount of viral entry, and overexpression of nectin-1 induced cytotoxicity by T-01 (Figure 2). In contrast, there was no correlation between the expression levels of the antiviral molecules and the cytotoxicity. Conclusion: Oncolytic HSV-1 has the potential for treatment of relapsed hematological malignancies. Entry via nectin-1 is a determining factor of susceptibility to oncolytic HSV-1 for hematological malignancies. Nectin-1 may be useful as a biomarker for efficacy of G47Δ. Disclosures Takaori-Kondo: Bristol-Myers Squibb: Honoraria, Research Funding; Ono: Research Funding; Takeda: Research Funding; Kyowa Kirin: Research Funding; Chugai: Research Funding; Janssen: Honoraria; Pfizer: Honoraria; Celgene: Honoraria, Research Funding; Novartis: Honoraria. Kadowaki:Takeda Pharmaceutical Company Ltd.: Honoraria, Research Funding; Taiho Pharmaceutical Co., Ltd.: Honoraria, Research Funding; Sumitomo Dainippon Pharma Co., Ltd.: Honoraria, Research Funding; Bristol-Myers Squibb Company: Honoraria, Research Funding; Asahi Kasei Pharma Corporation: Honoraria, Research Funding; Astellas Pharma Inc.: Honoraria, Research Funding; Chugai Pharmaceutical Co., Ltd.: Honoraria, Research Funding; Daiichi Sankyo Company Ltd.: Honoraria, Research Funding; Eisai Co., Ltd.: Honoraria, Research Funding; Kyowa Kirin Co., Ltd.: Honoraria, Research Funding; Merck & Co., Inc.: Honoraria, Research Funding; Ono Pharmaceutical Co., Ltd.: Honoraria, Research Funding; Otsuka Pharmaceutical Co., Ltd.: Honoraria, Research Funding; Novartis AG: Honoraria, Research Funding; Pfizer Japan Inc.: Honoraria, Research Funding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Maestro_S的应助被111采纳,获得10
1秒前
易迅发布了新的文献求助10
1秒前
万能图书馆的应助被柯迎南采纳,获得10
1秒前
1秒前
1秒前
1秒前
搜集达人的应助被安哥拉兔采纳,获得30
2秒前
7895764发布了新的文献求助10
2秒前
羞涩的恋风完成签到,获得积分10
2秒前
雷丹完成签到,获得积分20
2秒前
彭彭完成签到,获得积分10
2秒前
博客语法完成签到 ,获得积分10
2秒前
3秒前
ahfl发布了新的文献求助10
4秒前
lz发布了新的文献求助10
4秒前
4秒前
火花完成签到,获得积分10
5秒前
无花果的应助被JJKK采纳,获得10
5秒前
宇文念真完成签到,获得积分10
5秒前
凉宫半夏发布了新的文献求助10
5秒前
Atom发布了新的文献求助10
6秒前
6秒前
LLL发布了新的文献求助30
7秒前
夏侯乘风发布了新的文献求助10
7秒前
虚拟的信封完成签到,获得积分10
8秒前
在水一方的应助被一只彩虹驴采纳,获得10
8秒前
9秒前
lz完成签到,获得积分20
9秒前
amandaL完成签到,获得积分10
9秒前
9秒前
雪白小丸子完成签到,获得积分10
10秒前
11秒前
朝俞完成签到 ,获得积分10
11秒前
上官若男的应助被anyway采纳,获得10
11秒前
11秒前
12秒前
静静发布了新的文献求助10
12秒前
谨慎觅露发布了新的文献求助10
12秒前
科研通AI6.2的应助被念利伟采纳,获得10
13秒前
科研通AI6.4的应助被小浪矢采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192209
求助须知:如何正确求助?哪些是违规求助? 9578801
关于积分的说明 21861940
捐赠科研通 7791695
什么是DOI,文献DOI怎么找? 3436846
关于科研通互助平台的介绍 2560562
邀请新用户注册赠送积分活动 2483617